HC Wainwright Raises Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – HC Wainwright increased their FY2026 earnings per share estimates for Disc Medicine in a research note issued on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($6.19) for the year, up from their prior forecast of ($6.64). HC Wainwright has a “Buy” rating and a $127.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.20) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2026 earnings at ($1.47) EPS, Q2 2027 earnings at ($1.87) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($0.86) EPS, FY2027 earnings at ($5.56) EPS, FY2028 earnings at ($4.01) EPS, FY2029 earnings at $0.78 EPS and FY2030 earnings at $6.23 EPS.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley lifted their target price on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Truist Financial increased their price target on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Wells Fargo & Company raised their price objective on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Finally, Guggenheim began coverage on Disc Medicine in a research report on Monday. They set a “buy” rating and a $132.00 price objective on the stock. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $124.18.

Read Our Latest Stock Analysis on IRON

Disc Medicine Stock Up 2.9%

Shares of NASDAQ IRON opened at $87.08 on Tuesday. The firm has a fifty day simple moving average of $71.52 and a two-hundred day simple moving average of $71.05. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a current ratio of 20.30, a quick ratio of 24.14 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $3.34 billion, a PE ratio of -13.74 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.10.

Insider Buying and Selling

In related news, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,515,410.88. This trade represents a 13.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Quisel sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $79.15, for a total value of $2,611,950.00. Following the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 167,242 shares of company stock worth $13,124,591 in the last 90 days. Insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds have recently added to or reduced their stakes in IRON. State of Wyoming bought a new position in shares of Disc Medicine during the second quarter valued at $25,000. Allworth Financial LP purchased a new position in shares of Disc Medicine in the 2nd quarter worth about $46,000. Sterling Capital Management LLC raised its position in shares of Disc Medicine by 842.4% in the 3rd quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock worth $61,000 after purchasing an additional 834 shares during the last quarter. Nykredit A S purchased a new position in shares of Disc Medicine in the 2nd quarter worth about $103,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in Disc Medicine in the 3rd quarter worth about $119,000. 83.70% of the stock is owned by institutional investors.

Latest Disc Medicine News

Here’s some of the latest news about IRON:

  • Positive Sentiment: HC Wainwright reiterated its Buy rating and $127 price target. It raised estimates for several loss-making periods, including FY2026–FY2028, indicating a smaller projected loss in those years. Analysts’ reported consensus target is $124.18. HC Wainwright estimates Consensus price target
  • Neutral Sentiment: The short-interest item describes a significant increase but reports short interest of zero shares as of November 10. That inconsistency makes it difficult to interpret as a meaningful trading signal.
  • Negative Sentiment: HC Wainwright lowered its FY2029 and FY2030 earnings forecasts, though it still projects positive EPS in both years. This tempers the improved nearer-term estimates.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Featured Articles

Earnings History and Estimates for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.